Company Anterogen.Co.,Ltd.

Company Anterogen.Co.,Ltd.

A065660

KR7065660003

Pharmaceuticals

Equities

A065660

KR7065660003

Pharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Biopharmaceuticals

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sales per region

Sector Biopharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
15,360 ^KRW	+0.85%		+6.30%	-10.12%

2023	Anterogen.Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2021	Anterogen.Co.,Ltd. announced that it has received KRW 16 billion in funding from Shinhan Venture Investment Co, Ltd., NH Investment & Securities Co., Ltd., Investment Arm, SL Investment	CI

ANTEROGEN CO.,LTD. is a Korea-based company mainly engaged in the manufacture of cell therapy products. The Company's product portfolio consists of Cupistem which is used for the treatment of Crohnâs fistula by using autologous adipose-derived mesenchymal stem cells; stem cell conditioned medias (SCMs), SCM2s, and Therastem-dermas which are used for strengthening the function of skin as cosmetic raw materials; Remodullins which are used for the treatment of pulmonary arterial hypertension (PAH) and other products which are used for testing services. The Company distributes its products within domestic market.

KRW in Million	2022	Weight	2023	Weight	Delta
Cell Therapy Products and Rare Drugs Merchandise 82.4 %	5,934	90.0 %	5,356	82.4 %	-9.74%
Cell Therapy Products and Rare Drugs Product 17.6 %	657	10.0 %	1,142	17.6 %	+73.91%
Other 0.0 %	-	-	2	0.0 %	-

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 92.7 %	6,591	100.0 %	6,029	92.7 %	-8.53%
Overseas 7.3 %	-	-	472	7.3 %	-

Managers	Title	Age	Since
Mi-Hyung Kim CEO	Chief Executive Officer	55	04-02-29
Sung-Koo Lee CEO	Chief Executive Officer	69	00-03-15
In-Ok Kim CTO	Chief Tech/Sci/R&D Officer	48	02-08-31
Yoon-Jung Choi PRN	Corporate Officer/Principal	41	20-11-30
Tae-Hee Lee SAM	Sales & Marketing	-	18-09-30
Soon-Bae Kim AUD	Comptroller/Controller/Auditor	70	13-04-30

Members of the board	Title	Age	Since
Sung-Koo Lee CEO	Chief Executive Officer	69	00-03-15
Mi-Hyung Kim CEO	Chief Executive Officer	55	04-02-29
Sang-Soo Lee BRD	Director/Board Member	70	17-02-28
In-Ok Kim CTO	Chief Tech/Sci/R&D Officer	48	02-08-31
Choon-Taek Lim BRD	Director/Board Member	64	19-02-28
Tae-Hee Lee SAM	Sales & Marketing	-	18-09-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	9,731,373	7,537,711 ( 77.46 %)	0	77.46 %

Name	Equities	%	Valuation
Sung-Koo Lee 12.51 %	1,217,168	12.51 %	13 M ₩
EM-TECH.CO., LTD. 7.454 %	725,406	7.454 %	8 M ₩
Wan-soon Jang 0.9290 %	90,407	0.9290 %	941 290 ₩
Mi-Hyung Kim 0.8905 %	86,661	0.8905 %	902 287 ₩
In-Ok Kim 0.3109 %	30,252	0.3109 %	314 974 ₩
Tae-Hee Lee 0.1178 %	11,468	0.1178 %	119 401 ₩
Hye-mi Lee 0.1028 %	10,000	0.1028 %	104 117 ₩
Mirae Asset Global Investments Co., Ltd. 0.003329 %	324	0.003329 %	3 373 ₩
DFA Australia Ltd. 0.003268 %	318	0.003268 %	3 311 ₩

Name	Equities	%	Valuation
EM-TECH.CO., LTD. 8.64%	1,480,433	8.64%	36,258,351 $

Anterogen Co., Ltd.

Unit 405, Namsung Plaza 130 Digital-ro

08589, Seoul

http://www.anterogen.com

	1st Jan change	Capi.
ANTEROGEN.CO.,LTD.	-10.12%	108M
CSL LIMITED	-2.47%	89.37B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.65B
BIOGEN INC.	-13.89%	32.81B
UCB	+52.41%	25B
BIOMARIN PHARMACEUTICAL INC.	-17.32%	15.29B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.45%	11.61B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-10.48%	11.49B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	8.98B
INNOVENT BIOLOGICS, INC.	-7.72%	8.23B

Biopharmaceuticals

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Biopharmaceuticals